Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions. Therefore many companies in this sector are somewhat insulated from the impact of economic downturns. If they can remain ahead of the changes in their niches by being innovative, they can be successful over long periods.In other words, for those looking for "forever stocks," it's not a bad idea to look in this sector. And even with a modest sum -- such as $200 -- we can find excellent healthcare corporations to invest in for good. Here are two great examples: Bristol Myers Squibb (NYSE: BMY) and DexCom (NASDAQ: DXCM).The pharmaceutical industry is challenging to navigate. Developing novel medicines is risky and time-consuming, and comes with a maze of regulatory challenges. And drugmakers eventually face patent cliffs that erode the sales potential of even their best-selling drugs. Any company that can survive and thrive in this sector for a long time is worth serious consideration as a "forever stock."Continue reading

Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions. Therefore many companies in this sector are somewhat insulated from the impact of economic downturns. If they can remain ahead of the changes in their niches by being innovative, they can be successful over long periods.
In other words, for those looking for "forever stocks," it's not a bad idea to look in this sector. And even with a modest sum -- such as $200 -- we can find excellent healthcare corporations to invest in for good. Here are two great examples: Bristol Myers Squibb (NYSE: BMY) and DexCom (NASDAQ: DXCM).
The pharmaceutical industry is challenging to navigate. Developing novel medicines is risky and time-consuming, and comes with a maze of regulatory challenges. And drugmakers eventually face patent cliffs that erode the sales potential of even their best-selling drugs. Any company that can survive and thrive in this sector for a long time is worth serious consideration as a "forever stock."